Newly Established Veterinary Drugs Company Investment Opportunity in South San Francisco, United States

- Business focused on developing a portfolio of supervision-free medications for pets.

- The current product is a long-acting injectable designed to control pain in dogs with bone cancer.

- This product can also be prescribed off-label for other painful conditions in pets.

- The company plans to expand this drug delivery system to treat other conditions.

- The drug delivery platform is based on technology originally developed for humans, and the CEO was part of the development team.

- The company’s goal is to remove the burden of dosing, ensure adherence to prescriptions, and provide greater comfort to sick pets.

- Formulation, manufacturing and marketing is all outsourced.

- The company has developed prototypes of their products but is yet to conduct clinical trials and obtain FDA licensing.

- The business model is business-to-business (B2B), with plans to sell directly to veterinarians.

- Long-acting injectable to control pain in dogs with bone cancer.

- Can be prescribed off-label by vets for other painful conditions.

- This drug delivery system will be applied to treat other conditions in pets.

- The vet pharma market is resilient and growing as pet ownership increases worldwide.

No physical as the operations are currently virtual and drug manufacturing is outsourced.

The value of our company is in the intellectual property of our proprietary drug delivery platform.

Not operating from a dedicated facility.

We are a virtual company and will outsource to third party contractors the formulation, regulatory affairs and marketing.

These companies have been identified. Formulation will be done with contractor experienced in the development of long-acting injectables for human use.

The business is funded by the officers of the company. Total loans outstanding is $193,000 and the major shareholder is the CEO with an ownership of 93%.